Gaby L. Longsworth, Ph.D., is a Director in the Biotechnology/Chemical Group. Dr. Longsworth is sought out by both innovator and generic pharmaceutical companies for her insights and knowledge of intellectual property and brand product lifecycle management strategies.
A large part of Dr. Longsworth's practice is focused on representing international and domestic generic pharmaceutical companies in patent cases involving Abbreviated New Drug Applications (ANDAs) that include a Paragraph IV (pIV) certification to one or more Orange Book listed patents. She has been involved in multiple ANDA patent infringement cases brought under the Hatch-Waxman Act and has provided litigation and strategic advice concerning claim construction, invalidity and infringement issues, expert reports, and prepared experts for depositions. Dr. Longsworth has significant experience counseling clients on pIV filing strategies, including assessing the impact of data exclusivity, forfeiture issues (pre-MMA and post-MMA), label carve outs, and Patent Term Extensions (PTE).
Articles in the National Law Review database by Gaby L. Longsworth, Ph.D.